Rolapitant approved for chemotherapy-induced nausea and vomiting.
Kate
K
Traynor
D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017277:Drug Approval; D006801:Humans; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D013141:Spiro Compounds / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy*
D000932:Antiemetics; D000970:Antineoplastic Agents; D013141:Spiro Compounds; C578834:rolapitant